GenMont Biotech Inc (3164) - Total Assets
Based on the latest financial reports, GenMont Biotech Inc (3164) holds total assets worth NT$1.58 Billion TWD (≈ $49.75 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 3164 net assets for net asset value and shareholders' equity analysis.
GenMont Biotech Inc - Total Assets Trend (2003–2024)
This chart illustrates how GenMont Biotech Inc's total assets have evolved over time, based on quarterly financial data.
GenMont Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
GenMont Biotech Inc's total assets of NT$1.58 Billion consist of 31.7% current assets and 68.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 6.5% |
| Accounts Receivable | NT$33.33 Million | 2.0% |
| Inventory | NT$77.67 Million | 4.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$2.15 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how GenMont Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of GenMont Biotech Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GenMont Biotech Inc's current assets represent 31.7% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2024, up from 2.5% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 10.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 4.6% of total assets.
GenMont Biotech Inc Competitors by Total Assets
Key competitors of GenMont Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
GenMont Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.82 | 4.78 | 6.28 |
| Quick Ratio | 4.12 | 3.89 | 5.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$399.42 Million | NT$390.08 Million | NT$500.98 Million |
GenMont Biotech Inc - Advanced Valuation Insights
This section examines the relationship between GenMont Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.19 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | NT$1.71 Billion |
| Market Capitalization | $47.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values GenMont Biotech Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: GenMont Biotech Inc's assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GenMont Biotech Inc (2003–2024)
The table below shows the annual total assets of GenMont Biotech Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.71 Billion ≈ $53.83 Million |
+3.36% |
| 2023-12-31 | NT$1.65 Billion ≈ $52.08 Million |
-2.51% |
| 2022-12-31 | NT$1.70 Billion ≈ $53.43 Million |
-0.13% |
| 2021-12-31 | NT$1.70 Billion ≈ $53.50 Million |
+5.28% |
| 2020-12-31 | NT$1.61 Billion ≈ $50.81 Million |
+2.65% |
| 2019-12-31 | NT$1.57 Billion ≈ $49.50 Million |
-5.26% |
| 2018-12-31 | NT$1.66 Billion ≈ $52.25 Million |
+10.54% |
| 2017-12-31 | NT$1.50 Billion ≈ $47.26 Million |
+6.87% |
| 2016-12-31 | NT$1.40 Billion ≈ $44.23 Million |
-14.08% |
| 2015-12-31 | NT$1.63 Billion ≈ $51.47 Million |
-6.21% |
| 2014-12-31 | NT$1.74 Billion ≈ $54.88 Million |
+26.81% |
| 2013-12-31 | NT$1.37 Billion ≈ $43.28 Million |
-3.81% |
| 2012-12-31 | NT$1.43 Billion ≈ $45.00 Million |
-4.33% |
| 2011-12-31 | NT$1.49 Billion ≈ $47.03 Million |
+9.32% |
| 2010-12-31 | NT$1.37 Billion ≈ $43.02 Million |
+88.58% |
| 2009-12-31 | NT$724.10 Million ≈ $22.81 Million |
+6.34% |
| 2008-12-31 | NT$680.96 Million ≈ $21.45 Million |
+19.11% |
| 2007-12-31 | NT$571.68 Million ≈ $18.01 Million |
+9.74% |
| 2006-12-31 | NT$520.93 Million ≈ $16.41 Million |
+66.14% |
| 2005-12-31 | NT$313.55 Million ≈ $9.88 Million |
+1.45% |
| 2004-12-31 | NT$309.07 Million ≈ $9.74 Million |
+19.67% |
| 2003-12-31 | NT$258.26 Million ≈ $8.14 Million |
-- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan. It offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. The company was founded in 2000 and is based in Tainan City, Taiwan.